Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK

By Rothschild Sacha I.  

Cancers, Vol. 7, Iss. 2, 2015-05 ,pp. : 930-949

MDPI

Access to resources Recommend Favorite

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers

By Wei Jiacong   van der Wekken Anthonie J.   Saber Ali   Terpstra Miente M.   Schuuring Ed   Timens Wim   Hiltermann T. Jeroen N.   Groen Harry J. M.   van den Berg Anke   Kok Klaas  

Cancers, Vol. 10, Iss. 1, 2018-01 ,pp. : 10-10

MDPI

Access to resources Recommend Favorite

Non-Invasive Methods to Monitor Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?

By Ulivi Paola  

International Journal of Molecular Sciences, Vol. 17, Iss. 7, 2016-07 ,pp. : 1186-1186

MDPI

Access to resources Recommend Favorite

Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes

By Sharma Geeta Geeta   Mota Ines   Mologni Luca   Patrucco Enrico   Gambacorti-Passerini Carlo   Chiarle Roberto  

Cancers, Vol. 10, Iss. 3, 2018-02 ,pp. : 62-62

MDPI

Access to resources Recommend Favorite

Hsp90 Inhibitors and the Reduction of Anti-Cancer Drug Resistance by Non-Genetic and Genetic Mechanisms

By Lu Xiangyi   Wang Luan   Ruden Douglas M.  

Pharmaceuticals, Vol. 5, Iss. 9, 2012-08 ,pp. : 890-898

MDPI

Access to resources Recommend Favorite